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1. INTRODUCTION {#dom14057-sec-0001}
===============

In December 2019, unexplained viral pneumonia occurred in Wuhan, Hubei province, in China.[1](#dom14057-bib-0001){ref-type="ref"}, [2](#dom14057-bib-0002){ref-type="ref"} A novel coronavirus, later named COVID‐19 by the World Health Organization, was isolated from patients with this pneumonia.[^3^](#dom14057-bib-0003){ref-type="ref"} The clinical symptoms of COVID‐19 infection vary but mainly involve fever and cough. COVID‐19 mostly manifests as mild upper respiratory disease and gastrointestinal disease, severe viral pneumonia with systemic organ failure, or even death.[4](#dom14057-bib-0004){ref-type="ref"}, [5](#dom14057-bib-0005){ref-type="ref"} However, little attention has been paid to metabolic diseases caused by COVID‐19, especially in patients with diabetes mellitus.

2. MATERIALS AND METHODS {#dom14057-sec-0002}
========================

2.1. Study design and participants {#dom14057-sec-0003}
----------------------------------

Patients with COVID‐19 who died or were discharged during the period from January 1 to March 3, 2020, were included in this retrospective cohort study. The study protocol was approved by the Ethics Committee of the Central Hospital, and the requirement for informed consent was waived because of the retrospective nature of our research.

2.2. Data collection {#dom14057-sec-0004}
--------------------

Epidemiological, demographic and clinical data, as well as computed tomography (CT) images of lungs, laboratory investigations (viral nucleic acids test), treatment options, and management outcomes, were extracted from electronic medical records.

2.3. Definitions {#dom14057-sec-0005}
----------------

Ketosis was defined as positive urine ketone or serum ketone test results, while ketoacidosis was defined with a positive test result of urine ketone or serum ketone, and arterial pH \< 7.35 or carbon dioxide combining power \< 18 mmol/L.[6](#dom14057-bib-0006){ref-type="ref"}, [7](#dom14057-bib-0007){ref-type="ref"}

2.4. Statistical analysis {#dom14057-sec-0006}
-------------------------

Data are expressed as medians (interquartile range \[IQR\]) or percentages (%). We used the Mann--Whitney *U*‐test, the chi‐squared test or Fisher\'s exact test in order to compare the differences among various groups, including the differences between ketosis and non‐ketosis groups or between diabetes and non‐diabetes groups.

3. RESULTS {#dom14057-sec-0007}
==========

This study included 658 hospitalized patients with confirmed COVID‐19. Of these patients, 64 (9.7%) died, and 40 (62.5%) were men. The median (IQR) age was 57.5 (42.0--67.0) years, and 297 (45.1%) were men. The most common symptoms at disease onset were fever 441 (67.0%) and cough 258 (39.2%). Meanwhile, the majority of our patients had elevated levels of D‐dimer, C‐reactive protein and interleukin‐6, decreased levels of lymphocytes and albumin, and CT imaging features of ground‐glass opacification, which was consistent with previous studies.[1](#dom14057-bib-0001){ref-type="ref"}, [3](#dom14057-bib-0003){ref-type="ref"}

The characteristics and clinical outcomes of COVID‐19 patients with ketosis or non‐ketosis are summarized in Table [1](#dom14057-tbl-0001){ref-type="table"}. Forty‐two (6.4%) out of 658 patients presented with ketosis on admission, with no obvious fever or diarrhoea. They had a median (IQR) age of 47.0 (38.0--70.3) years, while 16 (38.1%) were men. Patients with ketosis were younger (median age 47.0 vs. 58.0 years; *P* = 0.003) and had a greater prevalence of fatigue (31.0% vs. 10.6%; *P* \< 0.001), diabetes (35.7% vs. 18.5%; *P* = 0.007) and digestive disorders (31.0% vs. 12.0%; *P* \< 0.001). They had a longer median (IQR) length of hospital stay (19.0 \[12.8--33.3\] vs. 16.0 \[10.0--24.0\] days; *P* \< 0.001) and a higher mortality rate (21.4% vs. 8.9%, *P* = 0.017).

###### 

Characteristics and clinical outcomes of patients with ketosis or non‐ketosis infected with COVID‐19

  Characteristic                                              All patients (n = 658)                          
  ----------------------------------------------------------- ------------------------ ---------------------- ----------
  **Age, years**                                              47.0 (38.0--70.3)        58.0 (43.0--67.0)      0.003
  **Gender, n (%)**                                                                                           
  Female                                                      26 (61.9)                335 (54.4)             0.441
  Male                                                        16 (38.1)                281 (45.6)             
  **Clinical symptoms**                                                                                       
  Temperature on admission, °C                                36.7 (36.5--37.4)        36.5 (36.3--36.9)      0.517
  Fever, n (%)                                                28 (66.6)                413 (67.0)             0.960
  Cough, n (%)                                                20 (47.6)                238 (38.6)             0.249
  Fatigue, n (%)                                              13 (31.0)                65 (10.6)              \<0.001
  Chest pain, n (%)                                           1 (2.4)                  14 (2.3)               1.000
  Chest tightness, n (%)                                      11 (26.2)                68 (11.0)              0.003
  Diarrhoea, n (%)                                            2 (4.8)                  16 (2.6)               0.731
  Headache, n (%)                                             2 (4.8)                  9 (1.5)                0.321
  Nausea and vomiting, n (%)                                  5 (11.9)                 39 (6.3)               0.280
  Shortness of breath, n (%)                                  11 (26.2)                92 (14.9)              0.052
  **Chronic disease, n (%)**                                                                                  
  Cerebrovascular disease                                     5 (11.9)                 48 (7.8)               0.513
  Coronary heart disease                                      6 (14.3)                 53 (8.6)               0.333
  Heart failure                                               2 (4.8)                  6 (1.0)                0.150
  Diabetes                                                    15 (35.7)                114 (18.5)             0.007
  Hypertention                                                12 (28.6)                208 (33.8)             0.490
  Digestive disorder                                          13 (31.0)                74 (12.0)              \< 0.001
  COPD                                                        0 (0)                    19 (28.8)              0.497
  Solid tumour                                                2 (4.8)                  15 (2.4)               0.677
  Chronic renal disease                                       1 (2.4)                  17 (2.8)               1.000
  Hepatitis                                                   1 (2.4)                  6 (1.0)                0.934
  **Complications, n (%)**                                                                                    
  Acute liver injury                                          6 (14.3)                 33 (5.4)               0.042
  Septic shock                                                3 (7.1)                  32 (5.2)               0.850
  Acute respiratory distress syndrome                         12 (28.6)                83 (13.5)              0.007
  DKA                                                         3 (7,1)                  0 (0)                  \< 0.001
  Acidosis                                                    5 (11.9)                 25 (4.1)               0.048
  **Lung CT images, n (%)**                                                                                   
  Unilateral pneumonia                                        14 (33.3)                137 (22.2)             0.098
  Bilateral pneumonia                                         28 (66.7)                479 (77.8)             0.098
  Multiple mottling and ground‐glass opacity                  27 (64.3)                412 (66.9)             0.730
  **Treatment strategies, n (%)**                                                                             
  Antibiotics                                                 41 (97.6)                481 (78.1)             0.002
  Antiviral drugs                                             41 (97.6)                576 (93.5)             0.461
  Antifungal agents                                           1 (2.4)                  17 (2.8)               1.000
  Hormones                                                    26 (61.9)                279 (45.3)             0.037
  Immunoglobulin                                              10 (23.8)                111 (18.0)             0.349
  Invasive mechanical ventilation                             9 (21.4)                 42 (6.7)               0.002
  Non‐invasive mechanical ventilation                         9 (21.4)                 63 (10.2)              0.046
  **Blood biochemical variables**                                                                             
  Leukocytes (3.5--9.5) 10^9^/L                               5.5 (3.5--9.1)           5.2 (4.1--6.7)         0.404
  Neutrophils (1.8--6.3) 10^9^/L                              3.8 (1.9--6.4)           3.4 (2.4--4.6)         0.069
  Lymphocytes (1.1--3.2) 10^9^/L                              1.1 (0.9--1.6)           1.2 (0.8--1.7)         0.410
  Eosinophils (0.02--0.52) 10^9^/L                            0.00 (0.00--0.03)        0.03 (0.00--0.09)      0.041
  Basophils (0--0.06) 10^9^/L                                 0.01 (0.01--0.02)        0.02 (0.01--0.02)      0.861
  Lymphocyte percentage (20%--50%)                            21.6 (11.7--31.7)        25.8 (15.9--34.6)      0.182
  Neutrophil percentage (40%--75%)                            68.5 (62.6--83.1)        64.5 (55.5--76.0)      0.096
  Monocyte percentage (3%--10%)                               6.6 (4.4--8.2)           7.0 (5.4--9.2)         0.519
  Eosinophil percentage (0.4%--8%)                            0.0 (0.0--0.6)           0.6 (0.1--1.7)         \<0.001
  Basophil percentage (0%--1%)                                0.2 (0.1--0.3)           0.3 (0.2--0.4)         0.022
  Platelets (125--350) 10^9^/L                                172.5 (145.0--222.8)     192.0 (154.0--247.0)   0.195
  Haemoglobin (130--175 g/L)                                  132.0 (120.8--140.8)     128.0 (119.0--139.0)   0.381
  Monocytes (0.1--0.6) 10^9^/L                                0.3 (0.2--0.5)           0.4 (0.3--0.5)         0.867
  Activated partial thromboplastin time (20--40) s            29.1 (25.1--31.3)        27.9 (24.9--31.0)      0.524
  Fibrinogen (2--4) g/L                                       2.9 (2.6--3.6)           2.8 (2.3--3.3)         0.073
  Prothrombin time (9--13) s                                  11.4 (10.8--11.7)        11.5 (11.0--12.0)      0.385
  International normalized ratio (0.7--1.3)                   1.0 (0.9--1.0)           1.0 (0.9--1.0)         0.406
  D‐dimer (0--1) μg/mL                                        0.7 (0.4--1.9)           0.5 (0.2--1.3)         0.632
  Albumin (40--55) g/L                                        39.4 (34.9--42.7)        39.5 (36.1--43.1)      0.542
  Globulin (20--40) g/L                                       28.4 (24.1--31.3)        26.9 (24.4--30.8)      0.757
  <https://www.ncbi.nlm.nih.gov/pubmed/29865856> (1.2--2.4)   1.4 (1.2--1.6)           1.5 (1.2--1.7)         0.639
  Alanine aminotransferase (9--50) U/L                        15.7 (10.9--28.8)        19.7 (13.8--34.3)      0.299
  Aspartate aminotransferase (15--40) U/L                     24.7 (16.8--37.3)        21.0 (16.0--30.6)      0.185
  Total bilirubin (2--20.4) μmol/L                            9.3 (6.2--13.8)          9.6 (7.0--13.6)        0.977
  Serum urea (1.7--8.3) mmol/L                                4.3 (3.0--5.9)           4.1 (3.2--5.4)         0.463
  Serum creatinine (57--111) μmol/L                           55.6 (42.4--65.2)        65.7 (52.0--79.8)      0.116
  Alkaline phosphatase (40--150) U/L                          60.8 (44.8--60.8)        60.8 (46.0--60.8)      0.266
  pH value (7.35--7.45)                                       7.42 (7.41--7.46)        7.42 (7.41--7.44)      0.463
  Creatine kinase (38--174) U/L                               91.5 (47.0--166.8)       88.0 (52.0--132.0)     0.437
  Lactate dehydrogenase (80--285) U/L                         214.6 (152.3--282.5)     191.0 (150.0--216.0)   0.264
  Creatine kinase isoenzyme (0--25) IU/L                      9.0 (6.0--11.5)          8.4 (6.0--10.3)        0.920
  Alpha‐hydroxybutyrate dehydrogenase (72--182) U/L           170.5 (119.8--216.0)     149.0 (118.3--167.0)   0.276
  γ‐Glutamyltransferase (10--60) U/L                          17.5 (13.6--34.3)        21.1 (13.3--38.9)      0.562
  Glucose (3.9--6.1) mmol/L                                   5.6 (4.7--10.5)          5.5 (4.8--6.9)         0.035
  Procalcitonin (\< 0.04) ng/mL                               0.11 (0.05--0.24)        0.05 (0.04--0.10)      0.834
  C‐reactive protein (0--0.5) mg/dL                           3.5 (1.4--6.5)           0.9 (0.1--3.4)         \<0.001
  Hospital stays, days                                        19.0 (12.8--33.3)        16.0 (10.0--24.0)      \<0.001
  **Clinical outcomes, n (%)**                                                                                
  Rehabilitation discharge                                    33 (78.6)                561 (91.1)             0.017
  Died                                                        9 (21.4)                 55 (8.9)               

Abbreviations: COPD, chronic obstructive pulmonary disease; CT, computed tomography; DKA, diabetic ketoacidosis.

Values are median (interquartile range), unless otherwise indicated.

The baseline characteristics and clinical outcomes of patients with and without diabetes and with ketosis who presented with COVID‐19 infection are summarized in Table [2](#dom14057-tbl-0002){ref-type="table"}. A total of 129 patients (19.6%) had diabetes, with only one case of type 1 diabetes (Table [1](#dom14057-tbl-0001){ref-type="table"}). Fifteen (35.7%, median age 56.0 years) out of 42 patients with ketosis had diabetes, while 27 (64.3%, median age 41.0 years) did not have diabetes. Patients with diabetes were older (median age 56.0 vs. 41.0 years; *P* = 0.008), with a greater prevalence rate of coronary heart disease (40.0% vs. 0%; *P* = 0.002) and hypertension (53.3% vs. 14.8%; *P* = 0.022), and also had a longer median (IQR) length of hospital stay (33.0 \[20.0--39.0\] vs. 17.0 \[10.0--22.0\] days; *P* = 0.003). However, we noted no significant difference regarding the mortality rate (33.3% vs. 14.8%; *P* = 0.313).

###### 

Characteristics and clinical outcomes of patients with or without diabetes with ketosis who were infected with COVID‐19

  Characteristic                                              Ketosis (n = 42)                              
  ----------------------------------------------------------- ---------------------- ---------------------- ---------
  **Age, years**                                              56.0 (49.0--73.0)      41.0 (30.0--56.0)      0.008
  **Gender, n (%)**                                                                                         
  Female                                                      12 (80.0)              14 (51.9)              0.072
  Male                                                        3 (20.0)               13 (48.1)              
  **Clinical symptoms, n (%)**                                                                              
  Temperature on admission,°C                                 36.8 (36.5‐37.5)       36.8 (36.4‐37.6)       0.094
  Fever                                                       10 (66.7)              18 (66.7)              1.000
  Cough                                                       7 (46.7)               13 (48.1)              0.927
  Fatigue                                                     7 (46.7)               6 (22.2)               0.196
  Chest pain                                                  0 (0)                  1 (3.7)                1.000
  Chest tightness                                             5 (33.3)               6 (22.2)               0.676
  Diarrhoea                                                   0 (0)                  2 (7.4)                0.746
  Headache                                                    1 (6.7)                1 (3.7)                1.000
  Nausea and vomiting                                         3 (20.0)               6 (22.2)               1.000
  Shortness of breath                                         3 (20.0)               8 (29.6)               0.754
  **Chronic disease, n (%)**                                                                                
  Cerebrovascular disease                                     4 (26.7)               1 (3.7)                0.088
  Coronary heart disease                                      6 (40.0)               0 (0)                  0.002
  Heart failure                                               1 (6.7)                1 (3.7)                1.000
  Hypertention                                                8 (53.3)               4 (14.8)               0.022
  Digestive disorder                                          4 (26.7)               9 (33.3)               0.858
  COPD                                                        0 (0)                  0 (0)                  NA
  Solid tumour                                                1 (6.7)                1 (3.7)                1.000
  Chronic renal disease                                       1 (6.7)                0 (0)                  1.000
  Hepatitis                                                   0 (0)                  1 (3.7)                1.000
  **Complications, %**                                                                                      
  Acute liver injury                                          2 (13.3)               4 (14.8)               1.000
  Septic shock                                                1 (6.7)                2 (7.4)                1.000
  Acute respiratory distress syndrome                         6 (40.0)               6 (22.2)               0.387
  DKA                                                         3 (20.0)               NA                     NA
  Acidosis                                                    3 (20.0)               2 (7.4)                0.478
  **Lung CT images, %**                                                                                     
  Unilateral pneumonia                                        3 (20.0)               11 (40.7)              0.172
  Bilateral pneumonia                                         12 (80.0)              16 (59.3)              0.172
  Multiple mottling and ground‐glass opacity                  7 (46.7)               20 (74.1)              0.076
  **Treatment strategies, %**                                                                               
  Antibiotics                                                 15 (100.0)             26 (96.3)              1.000
  Antiviral drugs                                             14 (93.3)              27 (100.0)             1.000
  Antifungal agents                                           0 (0)                  1 (3.7)                1.000
  Hormones                                                    10 (66.7)              16 (59.3)              0.636
  Immunoglobulin                                              4 (26.7)               6 (22.2)               1.000
  Invasive mechanical ventilation                             4 (26.7)               5 (18.5)               0.823
  Non‐invasive mechanical ventilation                         4 (26.7)               5 (18.5)               0.823
  **Blood biochemical parameters, median (IQR)**                                                            
  Leukocytes (3.5--9.5) 10^9^/L                               5.9 (4.0--12.2)        4.4 (3.1--7.9)         0.082
  Neutrophils (1.8--6.3) 10^9^/L                              4.5 (2.8--10.2)        3.7 (1.8--5.3)         0.053
  Lymphocytes (1.1--3.2) 10^9^/L                              1.0 (0.7--1.5)         1.2 (0.9--1.8)         0.548
  Eosinophils (0.02--0.52) 10^9^/L                            0.00 (0.00--0.01)      0.00 (0.00--0.06)      0.391
  Basophils (0--0.06) 10^9^/L                                 0.01 (0.01--0.02)      0.01 (0.01--0.02)      0.315
  Lymphocyte percentage (20%--50%)                            12.7 (7.4--22.9)       23.9 (15.9--35.5)      0.030
  Neutrophil percentage (40%--75%)                            82.3 (70.1--86.7)      66.9 (56.3--73.4)      0.029
  Monocyte percentage (3%--10%)                               5.4 (4.4--6.9)         7.2 (4.3--8.5)         0.255
  Eosinophil percentage (0.4%--8%)                            0.00 (0.00--0.20)      0.10 (0.00--1.00)      0.121
  Basophil percentage (0%--1%)                                0.2 (0.1--0.3)         0.2 (0.1--0.3)         0.781
  Platelets (125--350) 10^9^/L                                173.0 (146.0--201.0)   170.0 (132.0--242.0)   0.648
  Haemoglobin (130--175 g/L)                                  126.0 (116.0--134.0)   134.0 (123.0--144.0)   0.281
  Monocytes (0.1--0.6) 10^9^/L                                0.4 (0.2--0.6)         0.3 (0.2--0.5)         0.569
  Activated partial thromboplastin time (20--40) s            25.5 (23.3--30.0)      29.7 (27.5--32.6)      0.063
  Fibrinogen (2--4) g/L                                       3.5 (2.7--4.5)         2.8 (2.5--3.3)         0.072
  Prothrombin time (9--13) s                                  11.0 (10.6--11.6)      11.4 (11.1--11.9)      0.242
  International normalized ratio (0.7--1.3)                   1.0 (0.9--1.0)         1.0 (0.9--1.0)         0.214
  D‐dimer (0--1) μg/mL                                        1.0 (0.5--2.6)         0.6 (0.3--1.2)         0.163
  Albumin (40--55) g/L                                        35.6 (31.6--41.8)      40.8 (36.5--43.7)      0.017
  Globulin (20--40) g/L                                       29.5 (25.3--34.3)      28.2 (23.6--30.8)      0.261
  <https://www.ncbi.nlm.nih.gov/pubmed/29865856> (1.2--2.4)   1.3 (1.0--1.5)         1.5 (1.3--1.7)         0.029
  Alanine aminotransferase (9--50) U/L                        14.8 (10.9--33.3)      16.0 (10.9--28.5)      0.823
  Aspartate aminotransferase (15--40) U/L                     25.4 (18.3--45.6)      21.7 (16.6--32.8)      0.950
  Total bilirubin (2--20.4) μmol/L                            9.5 (5.6--19.8)        9.3 (6.6--11.3)        0.294
  Serum urea (1.7--8.3) mmol/L                                5.3 (3.6--6.9)         3.5 (2.9--4.7)         0.021
  Serum creatinine (57--111) μmol/L                           57.5 (40.7--65.6)      54.5 (45.8--63.9)      0.885
  Alkaline phosphatase (40--150) U/L                          60.8 (44.0--66.0)      55.0 (45.0--60.8)      0.768
  pH value (7.35--7.45)                                       7.43 (7.40--7.46)      7.42 (7.40--7.45)      0.961
  Ketone body (negative)                                      2 (1--2)               1 (1--2)               0.154
  Standard bicarbonate ion (21--25) mmol/L                    24.5 (19.5--26.4)      25.8 (25.8--27.4)      0.006
  Actual bicarbonate ion (21--28) mmol/L                      22.9 (19.0--26.0)      26.0 (25.0--28.1)      0.012
  Base excee (−3--3) mmol/L                                   3.2 (1.9--4.4)         3.2 (2.4--3.5)         0.721
  Lactate (0.5--2.2) mmol/L                                   1.3 (1.0--2.4)         2.1 (1.5--2.4)         0.417
  Creatine kinase (38--174) U/L                               128.0 (68.5--200.0)    77.0 (47.0--132.1)     0.633
  Lactate dehydrogenase (80--285) U/L                         253.0 (202.0--351.0)   202.0 (151.0--233.0)   0.345
  Creatine kinase isoenzyme (0--25) IU/L                      10.1 (9.0--15.0)       7.0 (6.0--11.0)        0.045
  Alpha‐hydroxybutyrate dehydrogenase (72--182) U/L           182.0 (158.0--257.0)   163.0 (116.0--190.0)   0.488
  γ‐Glutamyltransferase (10--60) U/L                          21.2 (15.4--37.0)      16.8 (12.9--34.1)      0.951
  Glucose (3.9--6.1) mmol/L                                   13.0 (9.2--16.6)       4.9 (4.6--5.6)         \<0.001
  HbA1c (\< 6%)                                               9.0 (7.6--12.3)        5.6 (5.2--5.8)         \<0.001
  Procalcitonin (\< 0.04) ng/mL                               0.21 (0.05--0.32)      0.09 (0.05--0.24)      0.175
  C‐reactive protein (0--0.5) mg/dL                           6.2 (2.9--8.8)         2.6 (0.7--4.9)         0.010
  Hospital stays, days                                        33.0 (20.0--39.0)      17.0 (10.0--22.0)      0.003
  **Clinical outcomes, n (%)**                                                                              
  Rehabilitation discharge                                    10 (66.7)              23 (85.2)              0.313
  Died                                                        5 (33.3)               4 (14.8)               

Abbreviations: COPD, chronic obstructive pulmonary disease; CT, computed tomography; DKA, diabetic ketoacidosis; HbA1c, glycated haemoglobin.

Values are median (interquartile range), unless otherwise indicated.

Three (20.0%) out of the 15 patients with diabetic ketosis developed acidosis (case 1: male, age 26 years, pH 6.86, urine ketone +++, fasting plasma glucose 22.61 mmol/L, urine glucose ++++, lactate 1.7 mmol/L; case 2: male, age 54 years, pH 7.22, urine ketone +++, fasting plasma glucose 21.23 mmol/L, urine glucose ++++, lactate 1.7 mmol/L; case 3: female, age 44 years, pH 7.32, urine ketone +, fasting plasma glucose 16.55 mmol/L, urine glucose ++++, lactate 0.7 mmol/L). Five patients (26.7%) with diabetic ketosis died, and one (25.0%) of these presented with acidosis. Two (7.4%) and four (14.3%) of the 27 patients with non‐diabetic ketotis developed severe acidosis (case 1: male, age 85 years, pH 7.11, urine ketone +, fasting plasma glucose 5.47 mmol/L, urine glucose negative, lactate 2.6 mmol/L; case 2: female, age 56 years, pH 7.15, urine ketone ++, fasting plasma glucose 4.63 mmol/L, urine glucose negative, lactate 1.0 mmol/L) and died, respectively, and one (25.0%) of those who died presented with acidosis.

Of the 42 patients with ketosis, four (44.4%) were men and their median (IQR) age was 69.0 ( 55.0--85.5) years, while nine patients (21.4%) died. All nine patients had a history of cardiovascular and cerebrovascular disease with no obvious history of respiratory disease, and died from multiple organ failure.

4. DISCUSSION {#dom14057-sec-0008}
=============

In the present study, we reported that COVID‐19 infection caused ketosis or ketoacidosis, and induced diabetic ketoacidosis (DKA) for those patients with diabetes. Ketosis increased the length of hospital stay and mortality. Meanwhile, diabetes increased the length of hospital stay for patients with ketosis but had no effect on their mortality.

Ketones are formed in the liver from free fatty acids.[^8^](#dom14057-bib-0008){ref-type="ref"} When ketone consumption decreases, it results in ketosis, which can be clinically evident by elevated blood concentrations of ketone bodies (β‐hydroxybutyrate, acetoacetate and acetone).[^9^](#dom14057-bib-0009){ref-type="ref"} Ketoacidosis, a severe metabolic disorder characterized by the accumulation of ketone bodies and acidosis, is mostly seen in people with diabetes and is rarely induced by other pathological conditions.[^10^](#dom14057-bib-0010){ref-type="ref"} In the present study, 42 patients with COVID‐19 had ketosis, including 27 who did not have diabetes. Meanwhile, five patients with COVID‐19 showed ketoacidosis, including three patients with diabetes and two without diabetes, which suggests that COVID‐19 might accelerate fat breakdown and induce ketosis, with further development of ketoacidosis. However, a previous study reported that patients with ketosis tended to have type 2 diabetes[^11^](#dom14057-bib-0011){ref-type="ref"}; therefore, non‐diabetic patients with ketosis should control their diet and exercise frequently to reduce the risk of diabetes. Further research is needed to confirm such observations.

Diabetic ketoacidosis is a potentially fatal metabolic complication attributable to uncontrolled blood glucose,[^12^](#dom14057-bib-0012){ref-type="ref"} which is more common in people with type 1 diabetes. However, it can also occur in type 2 diabetes and viral infection.[^13^](#dom14057-bib-0013){ref-type="ref"} In the present study, three patients with COVID‐19 had DKA, one of whom died. We should pay attention to COVID‐19 patients with ketoacidosis, therefore, especially those with diabetes, in order to reduce the associated mortality from complications of COVID‐19. Notably, the mechanism of COVID‐19‐induced DKA needs further research.

The study was limited because of the small number of patients with COVID‐19 progressing from ketosis to ketoacidosis. Future studies should pay considerable attention to ketosis and ketoacidosis in such a population, as well as observe the long‐term prognosis of the disease.

In conclusion, we reported that COVID‐19 infection caused ketosis or ketoacidosis, and induced DKA for those patients with diabetes. Ketosis increased the length of hospital stay and mortality. Meanwhile, diabetes increased the length of hospital stay for patients with ketosis but had no effect on their mortality. The mechanism of COVID‐19‐induced ketosis, ketoacidosis or DKA needs further research.
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